At-a-Glance Comparison

Why Amylin Is Being Studied for Weight Management

Amylin is a 37-amino-acid peptide hormone produced by pancreatic beta cells and co-secreted with insulin after nutrient intake. Its physiological actions include promoting satiation, slowing gastric emptying, and modulating post-meal glucagon secretion.

Native human amylin is difficult to develop directly because it is prone to aggregation and fibril formation and has a short circulating half-life. Drug developers therefore engineer analogs with altered amino acids, lipid attachments, or other modifications intended to improve solubility, stability, exposure, and dosing frequency.

Amylin Receptor Biology

Amylin receptors are formed when the calcitonin receptor associates with receptor activity-modifying proteins, known as RAMPs. Different RAMP combinations create receptor subtypes commonly described as AMY1, AMY2, and AMY3 receptors.

Receptor selectivity may influence efficacy, nausea-related pathways, food aversion, calcitonin-like effects, and overall tolerability. However, preclinical receptor profiles do not automatically predict the complete human clinical experience.

Eloralintide

Eloralintide is a long-acting selective amylin receptor agonist developed by Eli Lilly. Published preclinical work reported preferential activation of the human AMY1 receptor, with substantially lower activation of AMY3 and the calcitonin receptor in the tested systems.

Research rationale

• Preserve strong amylin-mediated weight-management signaling
• Reduce broader calcitonin-receptor activity
• Potentially improve gastrointestinal or aversion-related tolerability
• Support once-weekly exposure
• Allow monotherapy and combination development

In diet-induced obese rats, eloralintide reduced food intake and body weight, with weight loss arising primarily from fat mass in reported experiments. Lilly's preclinical paper also reported less conditioned taste avoidance than cagrilintide in a rat model, although that is not equivalent to a human nausea comparison.

Human evidence

A randomized Phase 2 study in adults with obesity or overweight reported dose-dependent weight reduction and a generally favorable tolerability profile. The candidate subsequently entered a broad Phase 3 ENLIGHTEN program, including studies in obesity without diabetes, obesity with type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity after incretin therapy.

Cagrilintide

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. It was engineered for once-weekly dosing and has been studied both as monotherapy and in fixed or co-administered combination with semaglutide, a GLP-1 receptor agonist.

Why cagrilintide is important

• It has one of the most mature clinical evidence bases among long-acting amylin analogs.
• Phase 2 monotherapy data established proof of concept for substantial weight reduction.
• It is the amylin component of CagriSema.
• Large Phase 3 combination trials provide extensive safety and efficacy information.
• Novo Nordisk is also advancing cagrilintide as monotherapy.

Cagrilintide has broader receptor pharmacology than the selectively designed eloralintide. It is commonly described as a nonselective amylin analog or an amylin/calcitonin receptor agonist in comparative research. That broader profile may contribute to both efficacy and adverse-effect differences, but direct human receptor-selectivity comparisons are incomplete.

Petrelintide

Petrelintide is a long-acting, acylated analog of human amylin originally developed by Zealand Pharma. Its molecular engineering was designed to improve chemical and physical stability, reduce fibrillation, support once-weekly dosing, and allow formulation at approximately neutral pH.

Distinct development goals

• Stable long-acting amylin pharmacology
• Neutral-pH formulation
• Reduced fibrillation tendency
• Clinically meaningful weight reduction with favorable tolerability
• Potential for combination or co-formulation with other peptide therapies

Phase 1 studies reported body-weight reductions with relatively limited gastrointestinal adverse events in small cohorts. In March 2026, Zealand announced Phase 2 ZUPREME-1 topline results showing average body-weight changes ranging from approximately −8.7% to −10.7% across petrelintide dose groups at week 42, compared with −1.7% for placebo under the reported efficacy estimand.

Zealand and Roche are developing petrelintide as monotherapy and in combinations, including a program with Roche's incretin candidate CT-388. Zealand announced advancement toward Phase 3 after the positive ZUPREME-1 results.

How Their Mechanistic Strategies Differ

Clinical Evidence: What Has Been Reported?

The studies differ in duration, dose escalation, participant characteristics, statistical estimands, and whether the drug was used alone or in combination. The figures below should not be treated as a ranking.

Tolerability Considerations

Amylin-based therapies can cause gastrointestinal effects, including nausea and vomiting, particularly during initiation or dose escalation. Appetite reduction, early fullness, constipation, diarrhea, and injection-site reactions may also be reported depending on the study.

Company descriptions such as “favorable” or “placebo-like” should be interpreted alongside the complete adverse-event table, discontinuation rates, dose-escalation scheme, event severity, and duration of exposure.

Body Composition and “Quality of Weight Loss”

Developers have increasingly highlighted whether weight reduction comes primarily from fat mass rather than lean mass. Preclinical experiments for eloralintide and petrelintide have reported favorable fat-versus-lean mass patterns. Human trials are also incorporating imaging and body-composition endpoints.

These claims require caution because:

• Animal body-composition findings may not translate directly to humans.
• Different imaging methods produce different measurements.
• Diet, protein intake, activity, age, sex, and baseline body composition affect lean mass.
• Percentage of weight loss from fat is not the same as zero lean-mass loss.
• Long-term functional outcomes matter more than a single scan.

Combination Strategies

Eloralintide combinations

Lilly is studying eloralintide with tirzepatide and with other metabolic candidates. The scientific rationale is that amylin-mediated satiation may complement incretin effects on appetite, glycemia, and energy intake.

Cagrilintide plus semaglutide

CagriSema combines or co-administers cagrilintide with semaglutide. Phase 3 trials have reported weight reductions exceeding either component alone in studied populations, although combination efficacy does not establish the independent value of every cagrilintide dose.

Petrelintide combinations

Zealand and Roche are advancing petrelintide with CT-388 and other potential combinations. Petrelintide's neutral-pH stability was designed partly to support co-formulation flexibility.

Development Status as of July 2026

Development programs can change rapidly. Trial initiation does not guarantee successful completion, regulatory submission, approval, commercial availability, or a favorable benefit-risk determination.

Why It Is Too Early to Declare a Winner

• No completed large direct head-to-head trial compares all three.
• The trials use different doses and titration schedules.
• Study durations differ.
• Some participants have type 2 diabetes and others do not.
• Baseline body weight and BMI differ.
• Sex distribution can affect observed response.
• Statistical estimands handle discontinuation differently.
• Company topline results contain less detail than full peer-reviewed papers.
• Combination results cannot be assigned entirely to the amylin component.
• Long-term cardiovascular, maintenance, and safety outcomes remain under study.

Research-Market Products and Analytical Testing

Eloralintide, cagrilintide, and petrelintide are proprietary investigational molecules. Products marketed online under these names should not be assumed to come from the pharmaceutical developer or to match the clinical-trial material.

A credible analytical packet should include

• Exact amino-acid sequence and structural modifications
• Theoretical molecular mass and observed LC-MS mass
• Lot-specific HPLC or UPLC purity data
• Quantitative peptide content per finished vial
• Counterion and water-content basis where relevant
• Full chromatogram and mass spectrum
• Batch traceability and verifiable laboratory identity

Common Misleading Comparisons

• “Eloralintide is proven superior because one short trial showed a larger percentage.”
• “Petrelintide has no GI effects.” Favorable averages do not mean no individual adverse events.
• “Cagrilintide and CagriSema are the same treatment.” One is an amylin analog; the other includes semaglutide.
• “All amylin analogs activate the same receptors equally.”
• “Selective AMY1 activity guarantees no nausea.”
• “Company topline results are equivalent to a complete peer-reviewed publication.”
• “Phase 3 means approved.”
• “A 99% purity COA proves the vial matches clinical-trial material.”

Frequently Asked Questions

Final Takeaway

Eloralintide, cagrilintide, and petrelintide represent three different approaches to long-acting amylin pharmacology. Eloralintide emphasizes selective AMY1 receptor activation. Cagrilintide has the most mature clinical development history and anchors the CagriSema combination. Petrelintide emphasizes molecular stability, neutral-pH formulation, and a potentially favorable balance between efficacy and tolerability.